AMRY BIO

CBMDA
CHINA BRITAIN MEDICAL AND DENTAL ASSOCIATION
CBMDA.ORG

CHINA-EUROPE
PHARMA OUTSOURCING & PARTNERSHIP CONGRESS AND DRUG DEVELOPMENT SUMMIT

20th - 22nd
SEPTEMBER
2018

CHENGDU - CHINA

媚博医疗科技
AMRY BIO

CBMDA
CHINA BRITAIN MEDICAL AND DENTAL ASSOCIATION
CBMDA.ORG

INVITATION

The global pharmaceutical industry is currently experiencing dynamic changes. Due to the high pressure of containing fixed costs all drug companies are reducing their internal capacities in R&D, marketing, manufacturing etc. in order to increase their outsourcing. Pharmaceutical companies big or small rely mainly on outsourcing service providers now more than ever to help solve problems, fulfil their tasks and improve efficiency and productivity. Thus it is crucial to create partnership opportunities to serve their individual needs.

The three-day China-Europe Pharma Outsourcing & Partnership Congress will provide a unique platform for the convergence of stakeholders in the industry to interact, discuss and network with top tier pharmaceuticals, biopharmaceuticals and biotechnology companies as well as regional and local service providers to discuss and share on the outsourcing and partnership strategies, challenges and opportunities, global collaboration and the future of pharma outsourcing and partnership.

Pharma Outsourcing & Partnership Congress

Roundtable Discussions (One/Many to Many)

These interactive and informal discussion groups are the hallmark of the meeting. Small exclusive groups of Leaders who face shared challenges and strategic priorities are brought together in 60-minute sessions that enable participants to share ideas and lessons learned. Facilitated by experienced professionals, these sessions provide a valuable dialogue with peers on current challenges and topical issues. Each discussion group has limited numbers which ensures each delegate is given ample opportunity to raise questions and contribute to the discussion.

One-to-One Meetings

The most effective and time efficient way to assess potential partners at a strategic level. Compare and update your knowledge of the industry in 40-minute informative and relaxed business meetings with solution providers of your choice.

Personalized Agenda

Each delegate receives a personalised agenda combining industry-leading keynote presentations, topical roundtable discussions, networking and business meetings. You only attend sessions and meetings that fit your challenges and interests, ensuring your time out of the office is focused and well-utilised.

Online Community

Our online community www.cbmda.org, enables the roundtable discussion to be prolonged and shared globally competitive environment. We keep the leaders connected in a user friendly platform.

Participants

Europe：Top 20 Pharmaceutical companies EVPs, SVPs, VPs, Executive Directors, Directors and Global Heads and Biotech CXOs
China：Departments Heads, Business Development Directors, CXOs, Global Partnership Directors.

CBMDA Consulting
1 Primrose Street, London, UK. EC2A 2EX
Phone: +44 (0) 208 352 3121
W: www.cbmda.org | E: info@cbmda.org

媚博医疗科技
AMRY BIO

CBMDA
CHINA BRITAIN MEDICAL AND DENTAL ASSOCIATION
CBMDA.ORG

DRUG DEVELOPMENT SUMMIT

Drug Discovery

Drug Discovery focuses on discussing the treatment strategies, risk management and consequences and challenges in drug design and discovery industry. This sector provides a platform to critically analyse and understand the methods and mechanisms.

Clinical Trial Outsourcing

Building on the success from our past European conferences, we will bring together professionals working within clinical operations and outsourcing across Europe and China. Our agenda incorporated the key challenges experienced in operations and outsourcing of clinical trials along with some new and exciting content and innovative sessions.

Manufacture and Supply Chain

There are a range of mechanisms that governments are using to rein in pharmaceutical spending and these are being implemented in various ways across the region. And s ome of these mechanisms affect the supply chain for pharmaceutical products. In this sector, we provide an unique platform for business knowledge sharing and convergence of top tier pharmaceuticals, biotechnology, as well as regional and local manufacturers to discuss and share on the macroeconomic factors, policies, issues and drivers that will steer the evolving supply chain in the pharmaceutical industry.

CBMDA Consulting
1 Primrose Street, London,
UK. EC2A 2EX
Phone: +44 (0) 208 352 3121
W: www.cbmda.org | E: info@cbmda.org

AMRY BIO 楣博医疗科技

CBMDA
CHINA BRITAIN MEDICAL AND DENTAL ASSOCIATION
CBMDA.ORG

AGENDA 20th September – 22nd September 2018

19th SEPTEMBER 2018

14:00-18:00 **Registration, Exibition Setup**

20th SEPTEMBER 2018

9:00-9:30 **Registration and Welcome Address**

9:30-12:30	**Innovation at the forefront of hit identification** · Identification of quality hits against targets of interest is of utmost importance in drug discovery. · Recent industry developments in all facets of this process have led to higher value starting points with potential to tackle more complex targets · Systematic evaluation of options and deployment of resources is essential to optimise success in hit identification space	Associate Director, Medicinal Chemistry **AstraZeneca**
	Long-term Sponsor: CRO Relationship · Which definition? Which market examples? · How to set up the relationship aimed to reach mutual creation of values · Are standard of practise of any economic benefit in the Sponsor – CRO long term relationship? · Key value creation principles and practical implementation examples - The continuous improvement pathway	Associate Director, Clinical Development Group, Asia Development Department **Daiichi Sankyo**
	Understand the supply chain and the lead times for each part of the supply chain: · What are the critical steps and timelines? · Increase visibility of the supplies across the supply chain: are the supplies in the required region? · Regular feedback on the actual study recruitment: where are the supplies required? · Understand the supply chain requirement at country level - what are the importation challenges, cost of shipping? · What is the best required strategy to manufacture (including packaging and labelling) the supplies?	Director of Clinical Trial Supplies **Eisai**
	Case study of semi-virtual biotech TopiVert from scratch to clinical proof-of-concept	Head of Medicinal Chemistry **TopiVert Pharma**

AGENDA 20th September – 22nd September 2018

20th SEPTEMBER 2018

12:30–13:30 **Lunch**

13:30–17:30	**Drug discovery externalisation: What will this look like in 2020?** · What are the current trends in drug discovery externalisation? · What are the emerging strategies? · What are the optimal business models and deal structures? · What are the key capabilities that partners/providers will have to either maintain, grow or build in order to stay competitive? · What will the West vs East landscape look like by 2020 and who will the potential winners and losers be?	Global Head of External Science & Drug Discovery Global Discovery Chemistry **Sanofi**
	What are the main obstacles on the critical path to studystart-up? · Are there innovations in technology and process that canmake a difference? · How can metrics/benchmarks be used to asses productivityand quality? · How can pharma and CROs best partner to streamline thecritical path to dosing?	Clinical Program Leader Respiratory Global Clinical Sciences & Operations **GSK**
	Case Study: Successful Defense: Proposed Regulatory Starting Materials Changing The Game On Marketing Applications Worldwide · Assess EMA critical steps for covering a broad spectrum of manufacturing processes · Identify the higher risk of (EMA/FDA) agencies not accepting proposed starting materials designation · Consider the turning points of requiring to extend GMP process upstream and how agencies view regulatory starting materials in the marketing application · Understand the impact of regulatory agencies agreement on starting materials designation and the risks associated with supply chain invalidation and the impact of regulatory agencies agreement on starting materials designation: · How do you recover from delay in approval when converting proposed starting materials into GMP process intermediates	Senior Director of Pharmaceuti-cal Development, Manufacturing & Quality **Corbus Pharmaceuticals**

媚博医疗科技
AMRY BIO

CBMDA
CHINA BRITAIN MEDICAL AND DENTAL ASSOCIATION
CBMDA.ORG

AGENDA 20th September – 22nd September 2018

21st SEPTEMBER 2018

Roundtable	1-2-1 Meetings
8:30 – 9:30 **Open innovation and partnerships for an improved Lead Generation**	**8:30 – 9:10**
9:30 – 10:30 **How to maximise project success through communications and transparent engagements**	**9:10 – 9:50** **9:50 – 10:30**
10:30 – 10:45	**Tea Break**
10:45 – 11:45 **Key takeaways on developing and adapting continuous manufacturing processes for more complex products**	**10:45 – 11: 25**
11:45 – 12:45 **What risk-mitigating tactics should be implemented in a GxP-outsourced partnership?**	**11:25 – 12:05** **12:05 – 12:45**
12:45 – 13:45	**Lunch**

Four roundtables will be facilitated by European Delegates selected Chinese industry suppliers. Minimum 5 selection to qualify.

媚博医疗科技
AMRY BIO

CBMDA
CHINA BRITAIN MEDICAL AND DENTAL ASSOCIATION
CBMDA.ORG

AGENDA 20th September – 22nd September 2018

21st SEPTEMBER 2018

Roundtable	1-2-1 Meetings
13:45 - 14:45 **How has the importance of the changing landscape of patient recruitment and retention shifted focus?**	**13:45 - 14:25**
14:45 - 15:45 **Modelling and informatics support for safety and metabolism studies in early drug discovery projects**	**14:25 - 15:05**
	15:05 - 15:45
15:45 - 16:00	**Tea Break**
16:00 - 17:00 **New chemical biology technologies for target identification and highthroughput screening: Chemical Glycobiology and beyond**	**16:00 - 16:40**
17:00 - 18:00 **Ensuring a Strong Quality and Compliance Focus with CMOs, Partners, and Suppliers**	**16:40 - 17:20**
	17:20 - 18:00
18:00 - 19:00	**CANAPÉ & DRINKS RECEPTION**

Four roundtables will be facilitated by European Delegates selected Chinese industry suppliers. Minimum 5 selection to qualify.

媚博医疗科技
AMRY BIO

CBMDA
CHINA BRITAIN MEDICAL AND DENTAL ASSOCIATION
CBMDA.ORG

AGENDA 20th September – 22nd September 2018

22nd SEPTEMBER 2018

9:00–22:00 ONE DAY CONTINUE NETWORKING TOUR – LESHAN CHENGDU, CHINA



KEYNOTE DELEGATES - EUROPE

Drug Discovery

1. Bayard Huck — **Vice President, Global Head of Medicinal Chemistry,**
Merck Group

Bayard Huck is currently the Global Head of Medicinal Chemistry at Merck Biopharma (subsidiary of Merck KGaA). Bayard received his Ph.D. in Organic Chemistry from the University of Wisconsin – Madison. His medicinal chemistry experience ranges from driving multiple small molecule programs from concept to clinic, to leading multiple programs to clinical proof of concept. Currently, as Global Head of Medicinal Chemistry, Bayard oversees the medicinal chemistry efforts at Merck Biopharma in support of Immunology, Immuno- Oncology, and Oncology therapeutic areas.

2. Matthew Fyfe — **Director, Medicinal Chemistry**
TopiVert Pharma

Matthew joined London-based biotech TopiVert at its inception to spearhead its medicinal chemistry, CMC and intellectual property activities. He has 18 years of experience as a medicinal chemist and drug discoverer, having formerly held the position of Director of Drug Discovery at Oryzon in Barcelona and Director of Medicinal Chemistry at Prosidion in Oxford. Matthew has successfully led multiple projects in different therapeutic areas that have been purchased by major pharma companies. He obtained degrees from the University of Glasgow (BSc), Columbia University (MA) and the University of Birmingham (PhD) prior to postdoctoral studies at UCLA. In addition, he is a Chartered Chemist, a Fellow of The Royal Society of Chemistry, an author of more than 40 peer-reviewed publications and an inventor on over 70 patent applications.

3. Bing-Yan Zhu — **Sr. Scientist and Principal Outsourcing Manager**
Genentech

Dr. Bing-Yan Zhu is a Sr. Scientist and Principal Outsourcing Manager in the Department of Discovery Chemistry at Genentech. His current primary responsibilities are working with external CROs and internal medicinal chemistry teams to help drive small molecule drug discovery programs at Genentech. Dr. Bing-Yan Zhu is one of inventors for factor Xa inhibitor, Betrixaban which was recently approved by US FDA for the prophylaxis of venous thromboembolism (VTE). Prior to joining Genentech in 2004, Dr. Bing-Yan Zhu worked at several biotech companies including Quark Pharmaceuticals, COR Therapeutics and Biochem Pharma. Dr. Bing-Yan Zhu received his PhD degree in Organic Chemistry from the University of Alberta, Canada and his Bachelor degree in Organic Chemistry from Lanzhou University, China.

KEYNOTE DELEGATES - EUROPE

Drug Discovery

4. Ian Churcher — **Head Discovery Performance Unit**



GlaxoSmithKline

After working at Merck on Alzheimer's Disease for several years, Ian joined GSK and has led groups across a number of areas including fragment-based drug design, enhancing the GSK compound collection and providing scientific consultancy services to external collaborators. More recently, Ian has led the Protein Degradation area at GSK where the group is looking to tackle drug targets in new ways. Ian is also a visiting professor in the department of chemistry at the University of Oxford. Embracing new paradigms for an integrated drug discovery process How can we radically shorten lead optimisation processes using integrated screening or evolution processes?

5. Valdas Jurkauskas — **Senior Director of Pharmaceutical Development, Manufacturing & Quality**

Corbus Pharmaceuticals

Dr. Jurkauskas' expertise is in process development, drug substance and drug product manufacturing, commercial process validation, and regulatory filings. Prior to joining Corbus, Dr. Jurkauskas led Technical Operations at STA Pharmaceuticals Co., Ltd., a WuXi AppTec and Active Pharmaceutical Ingredient Process Development at Cubist Pharmaceuticals, which was acquired by Merck & Co., Inc.. He was a member of Chemical Development at Vertex Pharmaceuticals. Dr. Jurkauskas earned his PhD degree in Organic Chemistry at the Massachusetts Institute of Technology under the guidance of Profesor Stephen L. Buchwald.

6. Alexander Hillisch — **Director MedicinalChemistry**

Bayer

Alexander is Director of Medicinal Chemistry and Head of Computational Chemistry at Bayer AG, Wuppertal, Germany. His team supports drug discovery efforts in cardiology and ophthalmology indication areas with computational chemistry, chemoinformatics, in silico ADMET and structural bioinformatics techniques. From 1998 to 2003 he headed a research group at EnTec, a subsidiary of Schering AG. Alexander has a Ph.D. in biophysics and molecular modeling from the Institute of Molecular Biotechnology (IMB) as well as a Ph.D. and Diploma in Pharmacy from the University of Vienna. He is the author of 42 research papers, 59 patents and 2 books. Alexander teaches Molecular Pharmacology and Drug Design at the University of Cologne from where he received an honorary professorship.

KEYNOTE DELEGATES - EUROPE

Clinical Trial Outsourcing

1. Paulo Moreira — **Vice President, Global Clinical Operations External Innovation**

Merck KGaA

Paulo Moreira is a Clinical Development executive with 26 years of experience in Clinical R&D. He has been with EMD Serono, the biopharma business of Merck KGaA Darmstadt, Germany for the last 16 years in diverse positions within Clinical Development. Presently serves as the Head of Global Clinical Operations External Innovation. In this capacity, Paulo is responsible for Clinical Innovation as well for Patient Centricity in Clinical Development and Operations where he has had a preponderant role in establishing EMD Serono as an industry leader in patient centricity around clinical trials.

2. Emanuel Lohrmann — **Lead Clinical Trial Risk Management**

Boehinger Ingelheim

After studying medicine, Emanuel Lohrmann worked in Drug Discovery at Bayer Healthcare and later switched to the Drug Safety Department at Bayer in 2005. In 2010, he joined CSL Behring as Head of the Risk Management Group within Global Drug Safety. He joined Merck KGaA (Darmstadt) in 2013 as head of Global Drug Safety Science and Epidemiology, responsible for the pharmaco-epidemiology group in Global Drug Safety and t he implementation of methods to improve signal management and benefit-risk assessment of products under development and post-approval. Since 2015 he is Lead Risk Management Physician at Boehringer Ingelheim.

3. Ana Sharma — **Global Head, Strategy and Operations, Clinical Development Quality**

Novartis

Ana Sharma is the Global Head, Strategy and Operations for Clinical Development Quality, at Novartis. Ana has thirteen years of experience in quality. She recently held positions such as Global Head, Pharmacovigilance Quality Assurance, Global Head, Clinical Quality Operations and Systems and Global Head, Clinical Quality Assurance Auditing. Ana has a Bachelor of Science degree in Biology and a Master of Public Health degree in Epidemiology and Biostatistics. Her personal and career interests are ensuring global public health.

KEYNOTE DELEGATES – EUROPE

Clinical Trial Outsourcing

4. Amer Alghabban

VP GxP Quality Assurance, Compliance & Training

Karyopharm Therapeutics

Amer is currently the VP of GxP Quality Assurance, Compliance at Karyopharm Therapeutics Inc. and also Managing Director of GxP Compliance and Training Partners (GCTP) helping pharmaceutical companies and academic institutions to achieve compliance with GCP, GVP, GCLP and GLP. Amer has over 27 years experience in the pharmaceutical industry. He has been an invited speaker at over 110 international congresses. Mr. Alghabban has published 2 reference books, The Pharmaceutical Medicine Dictionary and The Dictionary of Pharmacovigilance. He was Assistant Editor for 11 medical journals and an invited Course Director for Pharmacovigi lance Auditing at the UK RQA.

5. Shunichi Sasaki

Associate Director, Clinical Development Group, Asia Development Department

Daiichi Sankyo

Shunichi Sasaki, Associate Director, Clinical Development Group, is currently working at Daiichi Sankyo in Asia Development
Shun received his Ph.D in internal medicine from the Tokyo medical university. After graduate from the university in 1996, he started his carrier with Daiichi Sankyo in clinical development field and have been involved in contrast media, cardiovascular and oncology therapeutic area. He has was working experience in the US as an expats for several years and has robust experience in global studies including Asian countries, such as China, Korea, Taiwan etc.

6. Lidia Cappellina

Head of R&D Outsourcing Management

Chiesi Farmaceutici

Lidia is the Head of R&D Outsourcing Management for Chiesi Group. She has 25 years' experience in the pharmaceutical industry, started in 1992 in GSK Italy where she covered the role of Head of Licensing and License Management Department and subsequently she become the Head of Procurement. She moved in Astra Zeneca Italy in 2003 with the role of Strategic Business Development & Planning Director, and joined Chiesi in 2009.

KEYNOTE DELEGATES - EUROPE

Manufacture and Supply Chain

1. Steven Hu — **Senior Director & Head of CMC in Roche Pharm Research and Development (pRED)**

Roche

Steven Hu currently is the Senior Director & Head of CMC in Roche Pharm Research and Development (pRED) Shanghai, being responsible for process research and synthesis, analytical, preformulation and formulation development to support Roche China portfolio. Before joining Roche, Steven was the Director of New Product Development (NPD) of GSK China R&D, overseeing the whole drug product development life cycle from formulation development and optimization, process development and scale-up to technology transfer to commercial manufacturing.

2. Roman Necina — **Vice President, Process Development and Technical Services**

Shire

Roman Necina has been with Baxter since 2011 and is currently the Vice President of Process Science & Technical Operations at Baxalta and he also holds the title of General Manager Baxter Innovations. Roman has extensive experience in the pharma sector over a span of 25 years and has accomplished many achievements including Process Development, Tech Transfer, Scale-up and GMP production of drug substances and drug products for more than 40 different biologicals. His pharmaceutical career started in 1999 with Boehringer Ingelheim as a Protein Chemist where he rose to become Vice President Biopharmaceutical Production & Process Science before moving to Intercell in several senior management roles until 2011 after which he joined Baxter.

3. Richard Farquharson — **Executive Director, Distribution, Global Operations**

AstraZeneca

Richard is Head of Distribution & Logistics within the EMEA region for all AstraZeneca pharmaceutical products, this includes freight forwarding, warehousing activities and onward transportation to point of sale. This is delivered through a combination ofin-house DCs and outsourced LSPs. Richard chairs the AstraZeneca Global Distribution Network, which is responsible for the AZ distribution & logistics strategy, sets consistent standards and drives supply chain improvements working with R&D, Global Supply Chain & Commercial functions.

KEYNOTE DELEGATES - EUROPE

Manufacture and Supply Chain

4. Thibaud Stoll

Senior Vice President, Head Global Biotech Manufacturing & Development
Merck

Thibaud leads a global network of sites in charge of the technical development and manufacturing of biopharmaceuticals within the Healthcare division of the Merck Group. Prior to working at Merck, Thibaud held various positions of growing responsibility in biotech, pharma and vaccine companies, in both technical development and manufacturing. He has been Vice President for BelgiumOperations with GSK Vaccines and Head of Global Biopharmaceutical Opera tions at Novartis & Sandoz in Switzerland, in charge of clinical and commercial manufacturing of biopharmaceuticals and biosimilars. At Novartis, he has pioneered the implementation of LEAN to biomanu facturing. He started his career at Genentech, in California.

5. Felix Oehme

Vice President, Head of Biological Development
Bayer Pharma

Felix Oehme received his Ph.D. at the Max-Planck-Institute for Biochemistry, Munich. He joined Bayer in 1999 and worked as a head of laboratory in different areas of protein biochemistry with a focus on process development for antibodies and antibody fragments. As operations manager of a Biologics Pilot Plant from 2012-2016 he gained experience in clinical manufacturing of antibodies and anti body drug conjugates. In his current position as Head of Biological Development at Bayer in Wuppertal, Germany, Felix is leading a department focusing on upstream and downstream process devel opment as well as clinical manufacturing of biologics.

6. Luca Russo

Vice President, Head of Clinical Supply Chain
Johnson & Johnson

Luca Russo currently serves as Vice President and Head of Clinical Supply Chain at Janssen. Mr. Russo is globally accountable for the source, plan, make, delivery of the Janssen R&D supply chain, and further responsible for the support of clinical supplies - scale up from early to late stage development, as well as new product launches. Previously, Mr. Russo served as General Manager of Janssen's site in Latina, Italy. Mr. Russo has 18 years of experience in the operations and supply chain management of 2 major multinational USA corpo rations in consumer and pharma business. Asia: the challenges and the great potential Innovation and R&D for China.

媚博医疗科技
AMRY BIO

CBMDA
CHINA BRITAIN MEDICAL AND DENTAL ASSOCIATION
CBMDA.ORG

PAST PARTICIPANTS LIST -EUROPE

Drug Discovery

COMPANY	JOB TITLE
ABAC Therapeutics	CEO
Abbvie	Director Immunology Chemistry
Antikor Biopharma Ltd	Director Medicinal Chemistry
Astex Pharmaceuticals	VP of Discovery Technology
Astrazeneca	Global Head Research Outsourcing
AstraZeneca	Director Medicinal Chemistry iMed CVMD på
AstraZeneca	Associate Director Medicinal Chemistry
Boehringer Ingelheim	Director Medicinal Chemistry
Boehringer Ingelheim	Senior Vice President Research
Boehringer Ingelheim RCV GmbH & Co KG	Research Laboratory Head
Cancer Research Technology Discovery Laboratories	Senior Group Leader and Cambridge Site Lead
Domain Therapeutics	Head of Medicinal Chemistry
Eli Lilly	Group Leader, Medicinal Chemistry
Eli Lilly	Director Medicinal Chemistry
Eli Lilly and Company	Director External Innovation
F. Hoffmann-La Roche	External collaborations and technologies Manager
Galapagos	Head of Medicinal Chemistry RMV
Galderma	Lead Generation unit Manager
GlaxoSmithKline	Head Discovery Performance Unit
GlaxoSmithKline	Director of Computational Chemistry
Grunenthal	Senior Vice President, Global Drug Development
Janssen	Senior Director of Computational Chemistry
H. Lundbeck A/S	Head of Computational Chemistry
H. Lundbeck A/S	Chief Scientist & Senior Director Medicinal Chemistry
Medivir	Director Chemistry
Merck	Head of Medicinal Chemistry DA
Merck Group	Global Head Discovery Technologies
Merck KGaA	Vice President, Global Head of Medicinal Chemistry
Novartis	Director, Lead Generation Chemistry
Novartis Pharma AG	Executive Director, Drug Discovery
Novartis Pharma AG	Global Head of CPC (Center for Proteomic Chemistry)
Novartis Pharma AG	Head External Science & Drug Discovery, Global Discovery
Orion Corporation	Head of Medicinal Chemistry
Sanofi	Head of Medicinal Chemistry, R&D Sanofi Frankfurt
Sanofi	Head of Computational Structural Drug Design
Sanofi-Aventis	Global Head, External Innovation and Sourcing
Sanofi-Aventis Deutschland GbH	Director External Innovation
Takeda	Senior Director of Chemistry
UCB	Director of Chemistry Partnerships
UCB	Director of Medicinal Chemistry
Universoty of Bristol	Professor of Organic Chemistry,
Vernalis Ltd	Research Fellow
Vertex Pharmaceuticals	Head of Crystallography

媚博医疗科技
AMRY BIO

CBMDA
CHINA BRITAIN MEDICAL AND DENTAL ASSOCIATION
CBMDA.ORG

PAST PARTICIPANTS LIST -EUROPE

Clinical Trial Outsourcing

COMPANY	JOB TITLE
ABBVIE	Trial Operations Manager
Alexion	Associate Director Clinical Operations Lead
AstraZeneca	Associate Director Clinical Study Coordination
Astrazeneca	Director of Clinical Operations Strategy
Astrazeneca	Head of Clinical Operations
Bayer	Head Pharma Development Sourcing
Bayer	Business Intelligence and Evaluation Manager
Bayer	Senior Improvement Leader
Bayer	Category manager technology
Boehringer Ingelheim	RBM Project Implementation Lead
Boehringer-Ingelheim	Global Head Central Solutions and Services
Boehringer-Ingelheim	Medicine (CSSM) in Global Biostatistics & Data Sciences
Cancer Research UK	Head of Study, Project and Portfolio Management
Cancer Research UK	Head of Clinical Operations and Data Management
Celgene	Director, Clinical Monitoring
Daiichi Sankyo	Director, Data Management
Daiichi Sankyo Europe	Director, Clinical Operations
Diurnal Ltd	Head of Clinical Operations
Eisai	Director, Phase 1 Programming
Eisai	Asspciate Director, Clinical Operations
Eli Lilly	Director Clinical Operations for Oncology
Fujifilm Kyowa Kirin Biologics Ltd	Director of Clinical Operations
Grunenthal GmbH	Head Clinical Operations and Compliance
GSK	VP and Global Clinical Sciences and Operation
GSK	Head RW Study Delivery
GSK	Clinical Research Director
GSK	Director, Clinical Development
GSK	Director of Medical Operations
GSK	Vice President, Clinical Platforms Transformation
Institute of Cancer Research	Senior Clinical Trial Co-ordinator
Janssen	Senior Director, Head Clinical Biostatistics ID&V and GPH
Johnson & Johnson	IT Manager
Johnson and Johnson	Director, Integrated Data and Analytics
Karus Therapeutics	Head of Clinical Development
Lundbeck	Senior Manager, Clinical Operations
Novartis	Operations Expert, DevQA Quality & Compliance Excellence
Novo Nordisk	Clinical Program Leader
Novo Nordisk	Head of Global Development Outsourcing Management
Novo Nordisk	Vice President, Scientific Affairs R&D Portfolio
Onconova Therapeutics	Senior Director, Clinical Operations
Pfizer	Global Clinical Head
Pfizer	Associate Director, ePMF

媚博医疗科技
AMRY BIO

CBMDA
CHINA BRITAIN MEDICAL AND DENTAL ASSOCIATION
CBMDA.ORG

PAST PARTICIPANTS LIST -EUROPE

Manufacture and Supply Chain

COMPANY	JOB TITLE
Abbott Products Operations	Director of Global Distribution
Astellas	Head of Supply Chain
AstraZeneca	Head of Sourcing & Supply
AstraZeneca	Director Supply Chain Strategy
AstraZeneca	Senior Director, Supply Chain Management
AstraZeneca	Executive Director of Distribution, Global Operations
AstraZeneca	Global Supply Director
AstraZeneca	Executive Director Europe Supply Chain
Baxalta	Global Head Supply Chain, Sourcing & Procurement
Baxter Healthcare	Director Supply Chain Planning & Deployment
Baxter Healthcare	Program Director, Global SC Planning & Deployment
Bio Products Laboratory	Director, Supply Chain and Procurement
Boehringer Ingelheim Ltd	Head of Supply Chain Management
Boehringer Ingelheim Ltd	Corporate Director Supply Chain Integrity
Boehringer Ingelheim Ltd	Director, Head of Network Planning (GPO)
Bristol-Myers Squibb	Director – Supply Planning Centre of Excellence
Bristol-Myers Squibb	Executive Director, Logistics & Global Logistics Strategy Integration
Bristol-Myers Squibb	Associate logistics and Customer service manager
Celgene	Director, Clinical Supplies Operations
Daiichi Sankyo Development Ltd	Director of Clinical Trial Supplies
Eisai	Senior Director Supply and Demand Management
Eisai Manufacturing Ltd	Head of Corporate Demand Management
Ferrer	Head of End to End Logistics Partnership
GlaxoSmithKline	Supply Chain Planning Global Process Lead
GlaxoSmithKline	Supply Chain Logistics Business Partnering
GlaxoSmithKline	Director, Global Supply Chain Strategy & Innovation
GlaxoSmithKline	Vice President Global Supply Chain
IPSEN PHARMA	External Manufacturing
IPSEN PHARMA	Head of Technical & Quality- External Manufacturing
IPSEN PHARMA	Head of External Manufacturing Relationships
IPSEN PHARMA	Director, Global Distribution Procurement
Johnson & Johnson	EMEA Operations Process Director
Johnson & Johnson Medical Spa	Senior Manager Global Sourcing
Johnson & Johnson	Senior Vice President, Head of Global Supply Network Operations
Merck Group	

PAST CHINESE SUPPLIERS AND SERVICE PROVIDERS

1. Drug Discovery

Hutchison MediPharma
恒瑞
Crystal Pharmatech
齐鲁制药 QILU PHARMACEUTICAL
BeiGene
贝达药业 | BETA
药明康德 WuXi AppTec

2. Clinical Trial Outsourcing

BOJI 博济
Eliving
万邦医药
Venturepharma
Tigermed
合肥合源药业有限公司 HEFEI COSOURCE PHARMACEUTICALS INC.
Bionovo 博诺威——打造智慧医药
InCROM

3. Manufacture and Supply Chain

PORTON
ASYMCHEM
康龙化成 PHARMARON
BIODURO
Sundia
MabPlex
HISUN 海正药业

媚博医疗科技
AMRY BIO

CBMDA
CHINA BRITAIN MEDICAL AND DENTAL ASSOCIATION
CBMDA.ORG

SPONSORSHIP PACKAGES

No.	Type	Before 31st July 2018	After 31st July 2018
1	One to OneOutsourcing & Partnership meetings	15,000RMB	20,000RMB
	Including 2 representatives from vendor company, free participation in Drug Development Summit, 3 (three) pre-selected, pre-qualified one to one meetings. If selected by more buyers from European delegates list, 5000 RMB per extra meeting.		
2	Roundtable Discussion	15,000RMB	20,000RMB
	Including 2 representatives from vendor company, free participation in Drug Development Summit, Among 5 sessions under each topic, 2 roundtable meetings will be facilitated by European delegates selected Chinese industry suppliers. Minimum 5 selection to qualify. If selected by more buyers from European delegates list, 5000 RMB per extra meeting.		
3	Mix & Match	25,000RMB	30,000RMB
	Including 3 (three) pre-selected, pre-qualified one to one meetings and 1 (one) roundtable discussion.		
4	Drug Development Summit	2,000RMB	2,500RMB
	VIP pass to attend Drug Development Summit, discount apply for multiple participants from one orgnisation.		
5	Exibition	4,000RMB	5,000RMB
	Limited place availabie, please contact conference organiser for more information		
6	LeShan ChengDu Networking Tour	2,000RMB	2,500RMB
	Including meal and entry ticket. Opportunity for further networking during our one day tour with no restriction.		

For more information, please reach us using contact details below.

CBMDA Consulting
1 Primrose Street, London, UK. EC2A 2EX
Phone: +44 (0) 208 352 3121
W: www.cbmda.org | E: info@cbmda.org

CONTACT US

China

Judy Fang 方隽隽

Shanghai AmryBio Co., Ltd.
www.amrybio.com

Phone：021-59990301
Mobile: 15102198938
QQ：1991270962

Email：judy.fang@amrybio.com
Address: Room 1103 No. 2500 Zhenbei Road
Shanghai China. 200333

Europe

George Harington

Director, Strategic Partnership
CBMDA Consulting

CBMDA Consulting
www.cbmda.org

Phone：+44 (0) 77122 53095

Email：george.harington@cbmda.org
Address: 1 Primrose Street, London, EC2A 2EX

For more information, please scan and follow us on WeChat